

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/698,618	10/30/2003	Stina Gestrelius	S0002/7504D2	9884	
21127 7590 08/01/2007 RISSMAN JOBSE HENDRICKS & OLIVERIO, LLP ONE STATE STREET SUITE 800 BOSTON, MA 02109			EXAMINER		
			FORD, ALLISON M		
			ART UNIT	PAPER NUMBER	
,			1651		
			MAIL DATE	DELIVERY MODE	
	•		09/01/2007	DADED	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Supple Moutes

Notice of Allowability

Application No.	Applicant(s)		
10/698,618	GESTRELIUS ET AL.		
Examiner	Art Unit		
Allison M. Ford	1651		

			1
	Allison M. Ford	1651	
The MAILING DATE of this communication appeared all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate comming GHTS. This application is:	n this application. If not in unication will be mailed in	ncluded n due course. THIS
1. 🔀 This communication is responsive to telephonic interview of	of 23 July 2007.		•
2. X The allowed claim(s) is/are 50-53,56,59 and 61-72.			
<ol> <li>Acknowledgment is made of a claim for foreign priority under a)</li></ol>	been received. been received in Application	on No. <u>09/258,613</u> .	oplication from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the	ne requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EX. es reason(s) why the oath o	AMINER'S AMENDMENT declaration is deficient.	or NOTICE OF
<ol> <li>CORRECTED DRAWINGS (as "replacement sheets") must</li> <li>(a) including changes required by the Notice of Draftspers</li> <li>1) hereto or 2 to Paper No./Mail Date</li> <li>(b) including changes required by the attached Examiner's Paper No./Mail Date</li> <li>Identifying indicia such as the application number (see 37 CFR 1)</li> </ol>	con's Patent Drawing Review  s Amendment / Comment o	r in the Office action of	ot the back) of
each sheet. Replacement sheet(s) should be labeled as such in t	he header according to 37 Cl	R 1.121(d).	of the back) of
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT</li> </ol>	SIT OF BIOLOGICAL MAT FOR THE DEPOSIT OF BIO	ERIAL must be submitt DLOGICAL MATERIAL.	ed. Note the
Attachment(s)  1. Notice of References Cited (PTO-892)  2. Notice of Draftperson's Patent Drawing Review (PTO-948)  3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date  4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview S Paper No. 7. ⊠ Examiner's	oformal Patent Application ummary (PTO-413), /Mail Date <u>20070723</u> . Amendment/Comment Statement of Reasons fo	

Art Unit: 1651

## **EXAMINER'S AMENDMENT**

This examiner's amendment, and the attached Notice of Allowance, is intended to replace all previous examiner's amendments.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Therese Hendricks on 11 June 2007.

The application has been amended as follows:

## Claims:

Please re-write claim 51 as follows:

-- The method according to claim 50, wherein the active enamel substance is selected from the group consisting of enamelins, amelogenins, non-amelogenins, proline-rich non-amelogenins, amelins, tuftelins, and mixtures thereof. --

Please re-write claim 52 as follows:

-- The method according to claim 50, wherein the active enamel substance has a molecular weight of at the most about 120 kDa, as determined by SDS Page electrophoresis. --

Please re-write claim 53 as follows:

-- The method according to claim 50, wherein the amount of active enamel substance applied is an amount of total protein per cm<sup>2</sup> corresponding to from about 0.01 mg/cm<sup>2</sup> to about 20 mg/cm<sup>2</sup>. --

Application/Control Number: 10/698,618

Art Unit: 1651

Page 3

Please re-write claim 65 as follows:

-- The method according to claim 50, wherein the active enamel substance comprises a peptide comprising at least one sequence element selected from the group consisting of Asp-Gly-Glu-Ala (residues 370-373 of SEQ ID NO.: 1), Val-Thr-Lys-Gly (residues 277-280 of SEQ ID NO.: 1), Glu-Lys-Gly-Glu (residues 282-285 of SEQ ID NO.: 1), and Asp-Lys-Gly-Glu (residues 298-301 of SEO ID NO.: 1). --

Please re-write claim 72 as follows:

-- The method according to claim 53, wherein the amount of active enamel substance is from about 0.1 mg/cm<sup>2</sup> to about 15 mg/cm<sup>2</sup>. --

## Specification:

Please replace the title with the following:

-- MATRIX PROTEIN COMPOSITION FOR TREATING INFLAMMATION--

Please replace paragraph [0107] of the PGPubs with the following:

-- [0107] Within the scope of the present invention are also peptides as described in WO 97/02730, i.e. peptides which comprise at least one sequence element selected from the group consisting of the tetrapeptides DGEA (Asp-Gly-Glu-Ala) (residues 370-373 of SEQ ID NO.: 1), VTKG (Val-Thr-Lys-Gly) (residues 277-280 of SEQ ID NO.: 1), EKGE (Glu-Lys-Gly-Glu) (residues 282-285 of SEQ ID NO.: 1), and DKGE (Asp-Lys-Gly-Glu) (residues 298-301 of SEQ ID NO.: 1) and which further comprise an amino acid sequence from which a consecutive string of 20 amino acids is identical to a degree of at least 80% with a string of amino acids having the same length selected from the group

Art Unit: 1651

consisting of the amino acid sequence shown in SEQ ID NO:1 and a sequence consisting of amino acids 1 to 103 of SEQ ID NO:1 and amino acids 6 to 324 of SEQ ID NO:2. --

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Allison M. Ford whose telephone number is 571-272-2936. The examiner can normally be reached on 7:30-5 M-Th, alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system/call 800-786-9199 (IN USA OR

CANADA) or 571-272-1000.

Primary Examiner Art Unit 1651